Prolonged survival among women with BRCA germline mutations and advanced endometrial cancer: A case series

International Journal of Gynecological Cancer

Volumn 18, Issue 3, 2008, Pages 546-549

  Kwon, J S ^a   Lenehan, J ^b   Carey, M ^a   Ainsworth, P ^c  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b WESTERN UNIVERSITY   (Canada)

^c UNIVERSITY OF WESTERN ONTARIO   (Canada)

Author keywords

Advanced endometrial cancer; BRCA; Chemotherapy

Indexed keywords

ANTINEOPLASTIC AGENT; BRCA1 PROTEIN; BRCA2 PROTEIN; CARBOPLATIN; CISPLATIN; DOXORUBICIN; PACLITAXEL;

ADULT; ADVANCED CANCER; ARTICLE; CANADA; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CASE REPORT; ENDOMETRIUM CANCER; FEMALE; FOLLOW UP; GENE MUTATION; GERM LINE; HUMAN; HUMAN TISSUE; INHERITANCE; JEW; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; PROGNOSIS; UTERUS CARCINOMA;

CARCINOMA, ENDOMETRIOID; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; ENDOMETRIAL NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, BRCA1; GENETIC PREDISPOSITION TO DISEASE; GERM-LINE MUTATION; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; RISK ASSESSMENT; SAMPLING STUDIES; SURVIVAL RATE; TIME FACTORS;

EID: 43449112349     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1111/j.1525-1438.2007.01030.x     Document Type: Article

References (27)

1. Ben DY, Chetrit A, Hirsh-Yechezkel G et al. Effect of BRCA mutations on the length of survival in epithelial ovarian tumors. J Clin Oncol 2002 20 : 463 6.
2. Boyd J, Sonoda Y, Federici MG et al. Clinicopathologic features of BRCA-linked and sporadic ovarian cancer. JAMA 2000 283 : 2260 5.
3. Cass I, Baldwin RL, Varkey T, Moslehi R, Narod SA, Karlan BY. Improved survival in women with BRCA-associated ovarian carcinoma. Cancer 2003 97 : 2187 95.
4. Ramus SJ, Fishman A, Pharoah PD, Yarkoni S, Altaras M, Ponder BA. Ovarian cancer survival in Ashkenazi Jewish patients with BRCA1 and BRCA2 mutations. Eur J Surg Oncol 2001 27 : 278 81.
5. Carey MS, Gawlik C, Fung-Kee-Fung M, Chambers A, Oliver T. Systematic review of systemic therapy for advanced or recurrent endometrial cancer. Gynecol Oncol 2006 101 : 158 67.
6. Ontario Ministry of Health and Long-Term Care. 2006 : http://www.health.gov.on.ca/transformation/lhin/lhin_mn.html Accessed May 2007 2003 21 : 2397 2406.
7. Creasman WT, Odicino F, Maisonneuve P et al. FIGO Annual Report on the results of treatment in gynecological cancer: Carcinoma of the corpus uteri. Int J Gynecol Obstet 2003 83 (Suppl. 1 79 118.
8. Hendrickson M, Ross J, Eifel P, Martinez A, Kempson R. Uterine papillary serous carcinoma: a highly malignant form of endometrial adenocarcinoma. Am J Surg Pathol 1982 6 : 93 108.
9. Goff BA, Kato D, Schmidt RA et al. Uterine papillary serous carcinoma: patterns of metastatic spread. Gynecol Oncol 1994 54 : 264 8.
10. Cirisano FD Jr., Robboy SJ, Dodge RK et al. Epidemiologic and surgicopathologic findings of papillary serous and clear cell endometrial cancers when compared to endometrioid carcinoma. Gynecol Oncol 1999 74 : 385 94.
11. Hamilton CA, Cheung MK, Osann K et al. The effect of adjuvant chemotherapy versus whole abdominopelvic radiation on the survival of patients with advanced stage uterine papillary serous carcinoma. Gynecol Oncol 2006 103 : 679 83.
12. Slomovitz BM, Burke TW, Eifel PJ et al. Uterine papillary serous carcinoma (UPSC): a single institution review of 129 cases. Gynecol Oncol 2003 91 : 463 9.
13. Lambrou NC, Gomez-Marin O, Mirhashemi R et al. Optimal surgical cytoreduction in patients with Stage III and Stage IV endometrial carcinoma: a study of morbidity and survival. Gynecol Oncol 2004 93 : 653 8.
14. Bristow RE, Duska LR, Montz FJ. The role of cytoreductive surgery in the management of stage IV uterine papillary serous carcinoma. Gynecol Oncol 2001 81 : 92 9.
15. Bristow RE, Zerbe MJ, Rosenshein NB, Grumbine FC, Montz FJ. Stage IVB endometrial carcinoma: the role of cytoreductive surgery and determinants of survival. Gynecol Oncol 2000 78 : 85 91.
16. Goff BA, Goodman A, Muntz HG, Fuller AF Jr., Nikrui N, Rice LW. Surgical stage IV endometrial carcinoma: a study of 47 cases. Gynecol Oncol 1994 52 : 237 40.
17. Ayhan A, Taskiran C, Celik C, Yuce K, Kucukali T. The influence of cytoreductive surgery on survival and morbidity in stage IVB endometrial cancer. Int J Gynecol Cancer 2002 12 : 448 53.
18. Hornreich G, Beller U, Lavie O, Renbaum P, Cohen Y, Levy-Lahad E. Is uterine serous papillary carcinoma a BRCA1-related disease? Case report and review of the literature. Gynecol Oncol 1999 75 : 300 4.
19. Goshen R, Chu W, Elit L et al. Is uterine papillary serous adenocarcinoma a manifestation of the hereditary breast-ovarian cancer syndrome? Gynecol Oncol 2000 79 : 477 81.
20. Levine DA, Lin O, Barakat RR et al. Risk of endometrial carcinoma associated with BRCA mutation. Gynecol Oncol 2001 80 : 395 8.
21. Lavie O, Ben-Arie A, Pilip A et al. BRCA2 germline mutation in a woman with uterine serous papillary carcinoma-case report. Gynecol Oncol 2005 99 : 486 8.
22. Levine DA, Federici MG, Reuter VE, Boyd J. Cell proliferation and apoptosis in BRCA-associated hereditary ovarian cancer. Gynecol Oncol 2002 85 : 431 4.
23. Moynahan ME, Cui TY, Jasin M. Homology-directed dna repair, mitomycin-c resistance, and chromosome stability is restored with correction of a Brca1 mutation. Cancer Res 2001 61 : 4842 50.
24. Bhattacharyya A, Ear US, Koller BH, Weichselbaum RR, Bishop DK. The breast cancer susceptibility gene BRCA1 is required for subnuclear assembly of Rad51 and survival following treatment with the DNA cross-linking agent cisplatin. J Biol Chem 2000 275 : 23899 903.
25. Boulton SJ. Cellular functions of the BRCA tumour-suppressor proteins. Biochem Soc Trans 2006 34 : 633 45.
26. Lavie O, Hornreich G, Ben-Arie A et al. BRCA germline mutations in Jewish women with uterine serous papillary carcinoma. Gynecol Oncol 2004 92 : 521 4.
27. Mannucci PM. Treatment of von Willebrand's disease. N Engl J Med 2004 351 : 683 94.